Molecular determinants of outcomes in meningiomas

John Lynes; Gabriel Flores-Milan; Sebastian Rubino; John Arrington; Robert Macaulay; James K C Liu; Andre Beer-Furlan; Nam D Tran; Michael A Vogelbaum; Arnold B Etame

doi:10.3389/fonc.2022.962702

Molecular determinants of outcomes in meningiomas

Front Oncol. 2022 Aug 12:12:962702. doi: 10.3389/fonc.2022.962702. eCollection 2022.

Authors

John Lynes^{1

2}, Gabriel Flores-Milan^{1

2}, Sebastian Rubino^{1

2}, John Arrington³, Robert Macaulay⁴, James K C Liu^{1

2}, Andre Beer-Furlan^{1

2}, Nam D Tran^{1

2}, Michael A Vogelbaum^{1

2}, Arnold B Etame^{1

2}

Affiliations

¹ Division of Neurosurgery, Moffitt Cancer Center, Tampa, FL, United States.
² Department of Neuro-Oncology, Moffitt Cancer Center, Tampa, FL, United States.
³ Department of Radiology, Moffitt Cancer Center, Tampa, FL, United States.
⁴ Department of Pathology, Moffitt Cancer Center, Tampa, FL, United States.

Abstract

Meningiomas are the most common intracranial primary tumor in adults. Surgery is the predominant therapeutic modality for symptomatic meningiomas. Although the majority of meningiomas are benign, there exists a subset of meningiomas that are clinically aggressive. Recent advances in genetics and epigenetics have uncovered molecular alterations that drive tumor meningioma biology with prognostic and therapeutic implications. In this review, we will discuss the advances on molecular determinants of therapeutic response in meningiomas to date and discuss findings of targeted therapies in meningiomas.

Keywords: brain tumor; epigenetics; genetics; meningiomas; molecular classification; outcomes; targeted therapy.

Publication types

Review